Merrimack Pharmaceuticals Aktie
WKN DE: A1JHBG / ISIN: US5903281005
11.11.2014 06:21:27
|
Merrimack Pharma Q3 Loss Narrows, But Misses View; Stock Down
(RTTNews) - Merrimack Pharmaceuticals, Inc. (MACK) Monday reported a narrower third-quarter loss, which was worse than analysts had projected. The stock fell close to 5 percent in the extended trade.
Net loss was $28.0 million or $0.27 per share, compared to a loss of $39.6 million or $0.39 per share in the prior year.
On average, six analysts polled by Thomson Reuters expected the company to report a loss per share of $0.12 for the quarter. Analysts' estimates typically exclude special items.
Collaboration revenue increased to $28.0 million from $6.9 million last year. Analysts expected revenue of $21.79 million for the quarter.
The company attributed the revenue increase to a change in estimate of the revenue recognition period of previously-received upfront, milestone and manufacturing payments as a result of the termination of the MM-121 license and collaboration agreement with Sanofi.
Meanwhile, research and development expenses climbed 16 percent to $43.6 million.
Looking ahead, Merrimack said it expects its existing unrestricted cash and cash equivalents and available-for-sale securities as of September 30, of $153.7 million and anticipated cost sharing reimbursements from Baxter under their license and collaboration agreement related to MM-398 to be sufficient to fund operations into the second half of 2015.
Payments received from Baxter upon the achievement of milestones related to MM-398 would further extend Merrimack's cash runway, the firm added.
MACK closed unchanged at $8.70 on Monday, and dropped 4.8 percent in the extended trade.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Merrimack Pharmaceuticals Incmehr Nachrichten
Keine Nachrichten verfügbar. |